
## Emma L. Veale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5639934/publications.pdf

Version: 2024-02-01



EMMAL VEALE

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome. Genome Medicine, 2022, 14, .  | 8.2 | 6         |
| 2  | Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond. Annual Review of Pharmacology and Toxicology, 2021, 61, 401-420.  | 9.4 | 29        |
| 3  | Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092.<br>Biochemistry and Biophysics Reports, 2021, 26, 101021.   | 1.3 | Ο         |
| 4  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 2021, 178, S313-S411.   | 5.4 | 320       |
| 5  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. British Journal of Pharmacology, 2021, 178, S264-S312.   | 5.4 | 148       |
| 6  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. British Journal of Pharmacology, 2021, 178, S157-S245.  | 5.4 | 187       |
| 7  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. British Journal of Pharmacology, 2021, 178, S1-S26.   | 5.4 | 183       |
| 8  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors. British Journal of Pharmacology, 2021, 178, S246-S263.   | 5.4 | 100       |
| 9  | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 2021, 178, S412-S513.  | 5.4 | 114       |
| 10 | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein oupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.   | 5.4 | 337       |
| 11 | Effects of the ventilatory stimulant, doxapram on human TASKâ€3 (KCNK9, K2P9.1) channels and TASKâ€1<br>(KCNK3, K2P3.1) channels. Acta Physiologica, 2020, 228, e13361.  | 3.8 | 20        |
| 12 | Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during<br>the influenza vaccination season: A cross-sectional feasibility study. PLoS Medicine, 2020, 17, e1003197. | 8.4 | 10        |
| 13 | Title is missing!. , 2020, 17, e1003197.   |     | Ο         |
| 14 | Title is missing!. , 2020, 17, e1003197.   |     | 0         |
| 15 | Title is missing!. , 2020, 17, e1003197.   |     | Ο         |
| 16 | Title is missing!. , 2020, 17, e1003197.   |     | 0         |
| 17 | Title is missing!. , 2020, 17, e1003197.   |     | 0         |
| 18 | Title is missing!. , 2020, 17, e1003197.   |     | 0         |

2

Emma L. Veale

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein oupled receptors. British Journal of<br>Pharmacology, 2019, 176, S21-S141.  | 5.4 | 519       |
| 20 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 2019, 176, S142-S228.  | 5.4 | 242       |
| 21 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors. British Journal of Pharmacology, 2019, 176, S229-S246.   | 5.4 | 127       |
| 22 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 2019, 176, S247-S296.   | 5.4 | 156       |
| 23 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 2019, 176, S297-S396.   | 5.4 | 423       |
| 24 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology, 2019, 176, S397-S493.  | 5.4 | 166       |
| 25 | THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. British Journal of Pharmacology, 2019, 176, S1-S20.   | 5.4 | 295       |
| 26 | Pharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels. Scientific Reports, 2019, 9, 12394.   | 3.3 | 5         |
| 27 | Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2.<br>Biochemical and Biophysical Research Communications, 2019, 520, 35-40.   | 2.1 | 16        |
| 28 | Characterization and regulation of wildâ€ŧype and mutant TASKâ€┨ two pore domain potassium channels<br>indicated in pulmonary arterial hypertension. Journal of Physiology, 2019, 597, 1087-1101.                                  | 2.9 | 35        |
| 29 | Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol. BMJ Open, 2018, 8, e021121.   | 1.9 | 11        |
| 30 | Glâ€530159, a novel, selective, mechanosensitive twoâ€poreâ€domain potassium (K <sub>2P</sub> ) channel<br>opener, reduces rat dorsal root ganglion neuron excitability. British Journal of Pharmacology, 2018,<br>175, 2272-2283. | 5.4 | 40        |
| 31 | Activation of TREK currents by riluzole in three subgroups of cultured mouse nodose ganglion neurons. PLoS ONE, 2018, 13, e0199282.  | 2.5 | 15        |
| 32 | Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3.<br>Biochemical and Biophysical Research Communications, 2017, 493, 444-450.   | 2.1 | 27        |
| 33 | TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications. European Respiratory<br>Journal, 2017, 50, 1700754.   | 6.7 | 60        |
| 34 | Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic<br>nephropathy, is a regulator of K2P channels. British Journal of Pharmacology, 2016, 173, 1639-1652.                               | 5.4 | 30        |
| 35 | Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.<br>Pflugers Archiv European Journal of Physiology, 2015, 467, 931-943.  | 2.8 | 80        |
| 36 | Enhancement of TWIK-related Acid-sensitive Potassium Channel 3 (TASK3) Two-pore Domain Potassium<br>Channel Activity by Tumor Necrosis Factor α. Journal of Biological Chemistry, 2014, 289, 1388-1401.                            | 3.4 | 9         |

Emma L. Veale

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Influence of the N Terminus on the Biophysical Properties and Pharmacology of TREK1 Potassium<br>Channels. Molecular Pharmacology, 2014, 85, 671-681.  | 2.3 | 52        |
| 38 | Recovery of Current through Mutated TASK3 Potassium Channels Underlying Birk Barel Syndrome.<br>Molecular Pharmacology, 2014, 85, 397-407.   | 2.3 | 32        |
| 39 | Trafficking of Neuronal Two Pore Domain Potassium Channels. Current Neuropharmacology, 2010, 8,<br>276-286.  | 2.9 | 29        |
| 40 | SYMPOSIUM REVIEW: Gating of two pore domain potassium channels. Journal of Physiology, 2010, 588, 3149-3156.   | 2.9 | 68        |
| 41 | Dominant Negative Effects of a Non-conducting TREK1 Splice Variant Expressed in Brain*. Journal of<br>Biological Chemistry, 2010, 285, 29295-29304.  | 3.4 | 37        |
| 42 | The M1P1 Loop of TASK3 K2P Channels Apposes the Selectivity Filter and Influences Channel Function.<br>Journal of Biological Chemistry, 2008, 283, 16985-16992.  | 3.4 | 35        |
| 43 | TASK-3 Two-Pore Domain Potassium Channels Enable Sustained High-Frequency Firing in Cerebellar<br>Granule Neurons. Journal of Neuroscience, 2007, 27, 9329-9340.   | 3.6 | 109       |
| 44 | Gαq-Mediated Regulation of TASK3 Two-Pore Domain Potassium Channels: The Role of Protein Kinase C.<br>Molecular Pharmacology, 2007, 71, 1666-1675.   | 2.3 | 54        |
| 45 | Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide. British Journal of Pharmacology, 2007, 152, 778-786.  | 5.4 | 37        |
| 46 | Zinc and copper: Pharmacological probes and endogenous modulators of neuronal excitability. , 2006, 111, 567-583.  |     | 213       |
| 47 | The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the<br>α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists. Journal of Pharmacology and<br>Experimental Therapeutics, 2006, 317, 615-626. | 2.5 | 82        |
| 48 | Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite<br>norfluoxetine. British Journal of Pharmacology, 2005, 144, 821-829.   | 5.4 | 167       |
| 49 | Modifying the Subunit Composition of TASK Channels Alters the Modulation of a Leak Conductance in Cerebellar Granule Neurons. Journal of Neuroscience, 2005, 25, 11455-11467.  | 3.6 | 124       |
| 50 | Selective block of the human 2-P domain potassium channel, TASK-3, and the native leak potassium current, IKSO, by zinc. Journal of Physiology, 2004, 560, 51-62.  | 2.9 | 71        |
| 51 | What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?. Cerebellum, 2003, 2, 11-25.  | 2.5 | 48        |
| 52 | Neuronal ion channels and their sensitivity to extremely low frequency weak electric field effects.<br>Radiation Protection Dosimetry, 2003, 106, 311-315.   | 0.8 | 57        |
| 53 | What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?. Cerebellum, 2003, 2, 11-25.  | 2.5 | 3         |
| 54 | The sfr6 Mutation in Arabidopsis Suppresses Low-Temperature Induction of Genes Dependent on the CRT/DRE Sequence Motif. Plant Cell, 1999, 11, 875-886.   | 6.6 | 203       |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Map positions ofSFRgenes in relation to other freezing-related genes ofArabidopsis thaliana. Plant<br>Journal, 1999, 17, 445-452.   | 5.7 | 25        |
| 56 | A comparison of the in-vitro activity of amphotericin B with that of liposomal amphotericin B with<br>that of liposomal amphotericin B against Candida albicans colonising central venous catheters.<br>Journal of Antimicrobial Chemotherapy, 1994, 34, 840-841. | 3.0 | 2         |